Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Live Streamed
On Demand
Favorite
Facebook
Tweet
Print
Yayun Xu, PhD
Merck
Disclosure(s): No financial relationships to disclose
Poster(s):
(P-389) Switching to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily Maintains Viral Suppression Through Week 48 in the Presence of Archived NNRTI Resistance-Associated Mutations or M184I/V in Proviral DNA
Monday, October 20, 2025
12:15 PM - 1:30 PM
US ET
